German pharmaceutical firm BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its domestic rival CureVac, the firm said on Thursday.

(Reuters) -Pfizer and other drug companies have met with the Trump administration to discuss most-favored-nation pricing but ...

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

DelveInsight's Cancer Pain Market Insights report includes a comprehensive understanding of current treatment practices, ...

Pfizer is gearing up for a federal preemption defense, its first fight designed to wipe out more than 400 lawsuits over ...

What was holding up a deal appeared to be the lack of affordable units, as a previous proposal called for 420. However, NYC's ...

Findings indicate that frequent COVID-19 booster shots do not weaken T-cell responses, alleviating concerns for vulnerable ...

Pfizer and other drug companies have met with the Trump administration to discuss most-favored-nation pricing but no commitments have been made, Chief Executive Albert Bourla said on Monday at an ...

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

President Donald Trump's pick to be U.S. surgeon general has said the nation's medical and food systems are corrupted by ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...